Temodal 20 mg hard capsules
Sponsors
Inhibrx Biosciences Inc., TME Pharma AG, Hospital Foch, Laminar Pharmaceuticals S.A.
Conditions
Advanced or metastatic solid tumorsGlioblastomaGlioblastoma grade 4Newly diagnosed primary glioblastoma multiforme (ndGBM)
Phase 1
Single-arm dose-escalation Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter with a multiple-arm expansion group
RecruitingCTIS2024-510964-21-00
Start: 2019-09-12Target: 136Updated: 2025-11-18
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas.
RecruitingCTIS2023-508139-29-00
Start: 2024-06-26Target: 37Updated: 2025-10-09
Phase 2
A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment.
Active, not recruitingCTIS2024-511542-39-00
Start: 2019-09-16Target: 106Updated: 2025-10-01
Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide
Not yet recruitingCTIS2024-511026-31-01
Target: 59Updated: 2024-10-24